These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32775597)

  • 1. The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology.
    Handen BL; Lott IT; Christian BT; Schupf N; OBryant S; Mapstone M; Fagan AM; Lee JH; Tudorascu D; Wang MC; Head E; Klunk W; Ances B; Lai F; Zaman S; Krinsky-McHale S; Brickman AM; Rosas HD; Cohen A; Andrews H; Hartley S; Silverman W;
    Alzheimers Dement (Amst); 2020; 12(1):e12065. PubMed ID: 32775597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
    Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
    Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome.
    Belbin O; Xiao MF; Xu D; Carmona-Iragui M; Pegueroles J; Benejam B; Videla L; Fernández S; Barroeta I; Nuñez-Llaves R; Montal V; Vilaplana E; Altuna M; Clarimón J; Alcolea D; Blesa R; Lleó A; Worley PF; Fortea J
    Mol Neurodegener; 2020 Aug; 15(1):46. PubMed ID: 32807227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid age and tau PET timeline to symptomatic Alzheimer's disease in Down syndrome.
    Schworer EK; Zammit MD; Wang J; Handen BL; Betthauser T; Laymon CM; Tudorascu DL; Cohen AD; Zaman SH; Ances BM; Mapstone M; Head E; Klunk WE; Christian BT; Hartley SL;
    medRxiv; 2024 Aug; ():. PubMed ID: 39211859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.
    Hartley SL; Handen B; Tudorascu D; Lee L; Cohen A; Schworer EK; Peven JC; Zammit M; Klunk W; Laymon C; Minhas D; Luo W; Zaman S; Ances B; Preboske G; Christian BT;
    Alzheimers Dement; 2024 Jan; 20(1):366-375. PubMed ID: 37641428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing the emergence of amyloid and tau burden in Down syndrome.
    Zammit MD; Betthauser TJ; McVea AK; Laymon CM; Tudorascu DL; Johnson SC; Hartley SL; Converse AK; Minhas DS; Zaman SH; Ances BM; Stone CK; Mathis CA; Cohen AD; Klunk WE; Handen BL; Christian BT;
    Alzheimers Dement; 2024 Jan; 20(1):388-398. PubMed ID: 37641577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome.
    Gorijala P; Aslam MM; Dang LT; Xicota L; Fernandez MV; Sung YJ; Fan KH; Feingold E; Surace EI; Chhatwal JP; Hom CL; ; ; Hartley SL; Hassenstab J; Perrin RJ; Mapstone M; Zaman SH; Ances BM; Kamboh MI; Lee JH; Cruchaga C
    Alzheimers Dement; 2024 Feb; 20(2):1038-1049. PubMed ID: 37855447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood Biomarkers for Alzheimer's Disease in Down Syndrome.
    Montoliu-Gaya L; Strydom A; Blennow K; Zetterberg H; Ashton NJ
    J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of Down syndrome and Alzheimer's disease effects with imaging.
    Matthews DC; Lukic AS; Andrews RD; Marendic B; Brewer J; Rissman RA; Mosconi L; Strother SC; Wernick MN; Mobley WC; Ness S; Schmidt ME; Rafii MS
    Alzheimers Dement (N Y); 2016 Jun; 2(2):69-81. PubMed ID: 28642933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
    Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome.
    Henson RL; Doran E; Christian BT; Handen BL; Klunk WE; Lai F; Lee JH; Rosas HD; Schupf N; Zaman SH; Lott IT; Fagan AM
    Alzheimers Dement (Amst); 2020; 12(1):e12057. PubMed ID: 32671183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome.
    Neale N; Padilla C; Fonseca LM; Holland T; Zaman S
    Neuroimage Clin; 2018; 17():263-271. PubMed ID: 29159043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.
    Rafii MS; Zaman S; Handen BL
    J Prev Alzheimers Dis; 2021; 8(1):48-51. PubMed ID: 33336224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome.
    Rozalem Aranha M; Iulita MF; Montal V; Pegueroles J; Bejanin A; Vaqué-Alcázar L; Grothe MJ; Carmona-Iragui M; Videla L; Benejam B; Arranz J; Padilla C; Valldeneu S; Barroeta I; Altuna M; Fernández S; Ribas L; Valle-Tamayo N; Alcolea D; González-Ortiz S; Bargalló N; Zetterberg H; Blennow K; Blesa R; Wisniewski T; Busciglio J; Cuello AC; Lleó A; Fortea J
    Alzheimers Dement; 2023 Nov; 19(11):4817-4827. PubMed ID: 37021589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
    Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
    J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase.
    Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM
    Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study.
    Petersen ME; Zhang F; Schupf N; Krinsky-McHale SJ; Hall J; Mapstone M; Cheema A; Silverman W; Lott I; Rafii MS; Handen B; Klunk W; Head E; Christian B; Foroud T; Lai F; Rosas HD; Zaman S; Ances BM; Wang MC; Tycko B; Lee JH; O'Bryant S;
    Alzheimers Dement (Amst); 2020; 12(1):e12039. PubMed ID: 32626817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study.
    Hendrix JA; Airey DC; Britton A; Burke AD; Capone GT; Chavez R; Chen J; Chicoine B; Costa ACS; Dage JL; Doran E; Esbensen A; Evans CL; Faber KM; Foroud TM; Hart S; Haugen K; Head E; Hendrix S; Hillerstrom H; Kishnani PS; Krell K; Ledesma DL; Lai F; Lott I; Ochoa-Lubinoff C; Mason J; Nicodemus-Johnson J; Proctor NK; Pulsifer MB; Revta C; Rosas HD; Rosser TC; Santoro S; Schafer K; Scheidemantel T; Schmitt F; Skotko BG; Stasko MR; Talboy A; Torres A; Wilmes K; Woodward J; Zimmer JA; Feldman HH; Mobley W
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33924960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.